Further studies were conducted to explore the binding of anyof these proteins to the approved monoclonal antibodies for HNSCC.As shown in Figure 11, Pembrolizumab and Nivolumab show high affinity for binding to GTF2H4.Pembrolizumab and Nivolumab also bind to HAUS7, MSN, and MNDA proteinswith good affinity (Figures S19–S21). This evidence concerns the gene GTF2H4 and head and neck squamous cell carcinoma.